Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to compare the effects of three different doses of hydromorphone combined with ropivacaine and sufentanil combined with ropivacaine in epidural labor analgesia through prospective clinical trials, so as to explore whether hydromorphone combined with ropivacaine has advantages in epidural labor analgesia, and find out the optimal dose of hydromorphone.
Participants will be randomly allocated to four groups: H1 group,H2 group,H3 group and SF group.For those in H1 group: they will be administered with15 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in H3 group: they will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine for epidural labor analgesia, For those in SF group: they will be administered with 40 ug/ml sufentanil and 0.08% ropivacaine for epidural labor analgesia.
The goal of this clinical trial is to provide a new treatment option for pregnant women in epidural labor analgesia, and to provide a basis for hydromorphone combined with ropivacaine in epidural labor analgesia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| H1 group | Experimental | H1 group will be administered with15 ug/ml hydromorphone and 0.08% ropivacaine |
|
| H2 group | Experimental | H2 group will be administered with17.5 ug/ml hydromorphone and 0.08% ropivacaine |
|
| H3 group | Experimental | H3 group will be administered with 20 ug/ml hydromorphone and 0.08% ropivacaine |
|
| SF group | Active Comparator | SF group will be administered with 40 ug/ml sufentanil and 0.08% ropivacaine |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Hydromorphone | Drug | For those in H1 group: they will be administered with15 ug/ml hydromorphone, For those in H2 group: they will be administered with17.5 ug/ml hydromorphone , For those in H3 group: they will be administered with 20 ug/ml hydromorphone |
| Measure | Description | Time Frame |
|---|---|---|
| Visual Analogue Scale(VAS) | VAS will be monitored and recorded at 6 time points, including the time of entering the operating room(Time 0), when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), when the first dose is given for 30 minutes(Time 3), 30 minutes after delivery (Time 4), and 60 minutes after delivery (Time 5). The VAS consists of a 10 cm line,with two end points representing 0 (no pain) and 10 (pain as bad as it could possibly be). | 30 minutes-1 hour |
| Measure | Description | Time Frame |
|---|---|---|
| Heart rate(HR) | HR will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4). | 30 minutes-1.5 hours |
Not provided
Inclusion Criteria:
no contraindication of intraspinal anesthesia the American Society of Anesthesiologists(ASA) physical status ranked â… -â…¡ competent to provide informed consent
Exclusion Criteria:
poor respiratory functions severe cardiovascular diseases
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Na Li, MD | Maternal and Child Health Hospital of Hubei Province | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Maternal and Child Health Hospital of Hubei Province | Wuhan | Hubei | 430000 | China |
Not provided
| ID | Term |
|---|---|
| D000377 | Agnosia |
| D048949 | Labor Pain |
| ID | Term |
|---|---|
| D010468 | Perceptual Disorders |
| D019954 | Neurobehavioral Manifestations |
| D009461 | Neurologic Manifestations |
| D009422 | Nervous System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D004091 | Hydromorphone |
| D017409 | Sufentanil |
| D000077212 | Ropivacaine |
| ID | Term |
|---|---|
| D009022 | Morphine Derivatives |
| D009019 | Morphinans |
| D053610 | Opiate Alkaloids |
| D000470 | Alkaloids |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Sufentanil | Drug | For those in SF group: they will be administered with 40 ug/ml sufentanil |
|
| Ropivacaine | Drug | 0.08% ropivacaine will be co-administrated for epidural labor analgesia in four arms |
|
| Mean arterial pressure(MAP) |
MAP will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4). |
| 30 minutes-1.5 hours |
| Pulse oxygen saturation | Pulse oxygen saturation will be monitored and recorded at 5 time points, including the time of entering the operating room(Time 0),when the first dose is given for 5 minutes(Time 1), when the first dose is given for 15 minutes(Time 2), 30 minutes after delivery (Time 3), and 60 minutes after delivery (Time 4). | 30 minutes-1.5 hours |
| Duration of analgesia | Defined as the time from labor analgesia to delivery of the fetus. | 30 minutes-1.5 hours |
| The number of compressions | The number of compressions by electronic analgesia pump from labor analgesia to delivery of the fetus. | 30 minutes-1.5 hours |
| Adverse reactions | The occurrence of adverse reactions(nausea, vomiting, skin itching and other adverse reactions). | 30 minutes-1.5 hours |
| The Apgar scores | The Apgar scores of 1 and 5 minutes after birth will be recorded. | 30 minutes-1.5 hours |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010146 | Pain |
| D006571 |
| Heterocyclic Compounds |
| D006572 | Heterocyclic Compounds, Bridged-Ring |
| D006576 | Heterocyclic Compounds, 4 or More Rings |
| D000072471 | Heterocyclic Compounds, Fused-Ring |
| D010616 | Phenanthrenes |
| D011084 | Polycyclic Aromatic Hydrocarbons |
| D011083 | Polycyclic Compounds |
| D005283 | Fentanyl |
| D010880 | Piperidines |
| D006573 | Heterocyclic Compounds, 1-Ring |
| D000813 | Anilides |
| D000577 | Amides |
| D009930 | Organic Chemicals |
| D000814 | Aniline Compounds |
| D000588 | Amines |